Lung Cancer Drug By Pfizer Inc. (NYSE:PFE) Faces Rejection In UK Market


Dallas, Texas 08/19/2013 (Financialstrend) – Pfizer Inc. (NYSE:PFE) discovered a lung cancer drug Xalkori, which tentatively got rejected by an advisory board in Friday. The Drug has been strongly rejected for use in UK’s National Health Services.

The advisory board said that the drug, which is also known as crizotinib, was far too expensive and beyond the access of the common people. The National Institute for Health and Care Excellence said that the drug is too expensive for use in cash strapped universal health system despite the company’s offer of discounts.

Pfizer had once announced that it would cover part of the $ 80000 cost of treatment with Xalkori.

A draft guidance has been forwarded to other consultants who have the power to appeal the decision of rejection however, two years after Prime Minister David Cameron’s government made a push to cut about $31.2 billion from NHS budget the drugs’s rejection is expected to stay.

Also, The New York pharmaceutical giant has strongly criticized the methods of the institute of accessing drugs.

Recently Pfizer’s Bosulif drug meant to treat chronic myeloid leukemia also faced rejection.

A German Institute for Quality and Efficiency in Health Care, which is a cost assessing agency, also spurned the drug for its high price tag in the month of February.

Pfizer Continues To Sue Generics Makers In India

Despite the fact that it would bring no positive returns Pfizer Inc. (NYSE:PFE) continues to sue one if its Indian Generics Competitors. The company has yet again filled a lawsuit against Indian Generics competitors in a U.S court.

Also the Indian courts continue to hand down the ruling favourites to knock off competitive drug makers.

Pfizer sued Wockhardt Limited and two other Indian firms to restrict them from securing approvals to sell a generic version of its neuropathic painkiller Lyrica.

On Friday the Pfizer Corporation filled a lawsuit aginst two units of a Mumbai based firm to block a generic equivalent of its overactive bladder medication Toviaz.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.